Oramed Pharmaceuticals is pioneering innovative oral drug delivery technologies, particularly focusing on transforming injectable treatments into oral therapies. Their flagship product, ORMD-0801, is an oral insulin capsule designed to improve the lives of individuals with diabetes, especially type 2 diabetes patients, by allowing them to initiate insulin therapy without the discomfort associated with needles. This oral formulation not only enhances patient comfort and compliance but also reduces the risk of infection, making it a more appealing option for both adult and pediatric patients. The company is currently advancing ORMD-0801 through clinical trials, with promising results indicating its safety and efficacy in treating diabetes and non-alcoholic steatohepatitis (NASH).

In addition to ORMD-0801, Oramed is also developing ORMD-0901, an oral GLP-1 analog capsule that is currently in phase 1 trials. The oral delivery method offers several advantages, including first-pass metabolism that can enhance systemic exposure and overall cost-effectiveness. As the company continues to progress through various phases of clinical trials, it aims to establish itself as a leader in the oral drug delivery space, potentially becoming the first to market an oral insulin capsule for diabetes treatment. The advancements in their pipeline reflect a commitment to addressing significant unmet medical needs in diabetes and related conditions.

United States

Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. 

Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.  

Read more:  http://www.oramed.com/investors/corporate-presentation
Watch:  https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/ 

Endocrine System Diseases

Liver Diseases

Metabolic Diseases

Oramed Pharmaceuticals

Diabetes

Type 2 diabetes

ORMD-0801 is a novel oral human insulin formulated to increase hepatic insulin exposure, and subsequently reduce hepatic glucose production and improve glycemic control, with minimal hypoglycemia risk.&nbsp;
<a href="https://diabetes.diabetesjournals.org/content/69/Supplement_1/105-LB">Source</a>

Oramed Pharmaceuticals

Company Details